A pilot study of gonadotropin-releasing hormone agonist combined with aromatase inhibitor as fertility-sparing treatment in obese patients with endometrial cancer.
CONCLUSION: The combination of GnRH agonist and AI demonstrated promising long-term effect in young obese EC patients who wished to preserve their fertility. No weight gain side effects were observed. Further studies with a larger sample size are needed to fully evaluate this novel treatment regimen.
PMID: 31074242 [PubMed - as supplied by publisher]
Source: Journal of Gynecologic Oncology - Category: OBGYN Tags: J Gynecol Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Eating Disorders & Weight Management | Endometrial Cancer | Hormones | Men | Menopause | Obesity | OBGYN | Oral Cancer | Pregnancy | Reproduction Medicine | Study | Women